Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.

Breast Cancer Res Treat · 2020 · PMC7188712 · PMID 32323103

Europe PMC DOI

hedged sentence

0.1320

closest p · 2.6× alpha

0.1320

boldest claim

The sentences

showed a trendp = 0.132not close (p > 0.1)

The AE37 arm had no difference in DFS as compared to CG, but pre-specified exploratory subgroup analyses showed a trend towards benefit in advanced stage ( p = 0.132, HR 0.573 CI 0.275–1.193), HER2 under-expression ( p = 0.181, HR 0.756 CI 0.499–1.145), and triple-negative breast cancer ( p = 0.266, HR 0.443 CI 0.114–1.717).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.